Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Kathrin Heinrich

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

K. Heinrich1, V. Heinemann2, L. Müller3, P. Büchner-Steudel4, T.J. Ettrich5, S. Stintzing6, C. Schulz7

Author affiliations

  • 1 Haemato-oncology, University Hospital Munich, LMU, D- 81377 - Munich/DE
  • 2  department Of Medical Oncology And Comprehensive Cancer Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 3 Onkologie Leer, Studienzentrum Unter Ems, Leer/DE
  • 4 Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle/DE
  • 5 Department Of Internal Medicine I, Ulm Medical University, 89081 - Ulm/DE
  • 6 Medical Department, Division Of Oncology And Hematolgogy, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 7 Medizinische Klinik Und Poliklinik Iii, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
More

Resources

Background

S-1 has been shown to be an effective adjuvant treatment for East Asian patients who underwent gastrectomy with a D2 lymph-node dissection for stage II/III gastric cancer. We designed a phase I/II study to evaluate the efficacy, toxicity and feasibility of administering S-1 in the adjuvant setting after R0-Resection of adenocarcinoma of the stomach and esophagogastric junction in caucasian patients.

Methods

Eligible patients with histologically confirmed adenocarcinoma T2/T3/T4, any N category, M0 or any uT, N+, M0 of the stomach or esophago gastric junction had undergone R0-resection with or without neoadjuvant treatment and D2 lymph node dissection. They had performance status of ECOG 0-1 and adequate organ function. Treatment was orally administered S-1 (30mg/m² twice daily) for 14 days every three weeks for 18 cycles (54 weeks). A primary endpoint of the study is the determination of the recommended dose for S-1. Follow up will be continued until one year after last patient’s end of treatment.

Results

Between Oct 2015 and Feb 2018, 30 patients were enrolled in 12 German centres. Male/female ratio was 56.7%/43.3%, median age was 61.5 years. Of 30 patients included, 10 were diagnosed with gastric cancer, 20 with EGJ cancer (3 AEG I, 6 AEG II and 11 AEG III). Of 30 patients starting adjuvant therapy, 17 completed all 18 cycles, 2 patients had to terminate study treatment due to adverse events. Five patients terminated study treatment due to patients wish, 4 patients suffered a relapse or distant metastasis. Nine patients had to be reduced to dose level 25 mg/m², 1 patient had to be reduced to 20 mg/m². One patient was underdosed for the first 6 cycles and received full dosage from cycle 7. Of patients completing all 18 cycles, 5 had did so with reduced dosage of S-1. Documented grade ≥ 3 adverse events were neutropenia (n = 2), diarrhoea (n = 2), vomiting (n = 1), polyneuropathy (n = 1), palmar-plantar erythrodysaesthesia syndrome (n = 1) and rash (n = 1).

Conclusions

From this first analysis we can conclude that adjuvant treatment with S-1 for one year of patients suffering from gastric adenocarcinoma or EGJ cancer after R0-resection is a feasible and safe option for Caucasian patients.

Clinical trial identification

2014-004116-11.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien-gGmbH, Berlin.

Funding

Funded by AIO-Studien-gGmbH, supported by Taiho Pharmaceutical Co., Ltd and Nordic Pharma Group.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings